Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 151

1.

Zbtb7a suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion.

Wang G, Lunardi A, Zhang J, Chen Z, Ala U, Webster KA, Tay Y, Gonzalez-Billalabeitia E, Egia A, Shaffer DR, Carver B, Liu XS, Taulli R, Kuo WP, Nardella C, Signoretti S, Cordon-Cardo C, Gerald WL, Pandolfi PP.

Nat Genet. 2013 Jul;45(7):739-746. doi: 10.1038/ng.2654. Epub 2013 Jun 2.

2.

A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer.

Lunardi A, Ala U, Epping MT, Salmena L, Clohessy JG, Webster KA, Wang G, Mazzucchelli R, Bianconi M, Stack EC, Lis R, Patnaik A, Cantley LC, Bubley G, Cordon-Cardo C, Gerald WL, Montironi R, Signoretti S, Loda M, Nardella C, Pandolfi PP.

Nat Genet. 2013 Jul;45(7):747-55. doi: 10.1038/ng.2650. Epub 2013 Jun 2.

3.

Phosphorylation of the androgen receptor by PIM1 in hormone refractory prostate cancer.

Ha S, Iqbal NJ, Mita P, Ruoff R, Gerald WL, Lepor H, Taneja SS, Lee P, Melamed J, Garabedian MJ, Logan SK.

Oncogene. 2013 Aug 22;32(34):3992-4000. doi: 10.1038/onc.2012.412. Epub 2012 Sep 17.

4.

MYCN and MYC regulate tumor proliferation and tumorigenesis directly through BMI1 in human neuroblastomas.

Huang R, Cheung NK, Vider J, Cheung IY, Gerald WL, Tickoo SK, Holland EC, Blasberg RG.

FASEB J. 2011 Dec;25(12):4138-49. doi: 10.1096/fj.11-185033. Epub 2011 Aug 19.

5.

Identification of PHLPP1 as a tumor suppressor reveals the role of feedback activation in PTEN-mutant prostate cancer progression.

Chen M, Pratt CP, Zeeman ME, Schultz N, Taylor BS, O'Neill A, Castillo-Martin M, Nowak DG, Naguib A, Grace DM, Murn J, Navin N, Atwal GS, Sander C, Gerald WL, Cordon-Cardo C, Newton AC, Carver BS, Trotman LC.

Cancer Cell. 2011 Aug 16;20(2):173-86. doi: 10.1016/j.ccr.2011.07.013.

6.

MYC cooperates with AKT in prostate tumorigenesis and alters sensitivity to mTOR inhibitors.

Clegg NJ, Couto SS, Wongvipat J, Hieronymus H, Carver BS, Taylor BS, Ellwood-Yen K, Gerald WL, Sander C, Sawyers CL.

PLoS One. 2011 Mar 4;6(3):e17449. doi: 10.1371/journal.pone.0017449.

7.

Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases.

Yoshizawa A, Motoi N, Riely GJ, Sima CS, Gerald WL, Kris MG, Park BJ, Rusch VW, Travis WD.

Mod Pathol. 2011 May;24(5):653-64. doi: 10.1038/modpathol.2010.232. Epub 2011 Jan 21.

8.

Global levels of specific histone modifications and an epigenetic gene signature predict prostate cancer progression and development.

Bianco-Miotto T, Chiam K, Buchanan G, Jindal S, Day TK, Thomas M, Pickering MA, O'Loughlin MA, Ryan NK, Raymond WA, Horvath LG, Kench JG, Stricker PD, Marshall VR, Sutherland RL, Henshall SM, Gerald WL, Scher HI, Risbridger GP, Clements JA, Butler LM, Tilley WD, Horsfall DJ, Ricciardelli C; Australian Prostate Cancer BioResource.

Cancer Epidemiol Biomarkers Prev. 2010 Oct;19(10):2611-22. doi: 10.1158/1055-9965.EPI-10-0555. Epub 2010 Sep 14.

9.

Copy number and gene expression differences between African American and Caucasian American prostate cancer.

Rose AE, Satagopan JM, Oddoux C, Zhou Q, Xu R, Olshen AB, Yu JZ, Dash A, Jean-Gilles J, Reuter V, Gerald WL, Lee P, Osman I.

J Transl Med. 2010 Jul 22;8:70. doi: 10.1186/1479-5876-8-70.

10.

Integrative genomic profiling of human prostate cancer.

Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, Antipin Y, Mitsiades N, Landers T, Dolgalev I, Major JE, Wilson M, Socci ND, Lash AE, Heguy A, Eastham JA, Scher HI, Reuter VE, Scardino PT, Sander C, Sawyers CL, Gerald WL.

Cancer Cell. 2010 Jul 13;18(1):11-22. doi: 10.1016/j.ccr.2010.05.026. Epub 2010 Jun 24.

11.

TMPRSS2-ERG gene fusion is associated with low Gleason scores and not with high-grade morphological features.

Fine SW, Gopalan A, Leversha MA, Al-Ahmadie HA, Tickoo SK, Zhou Q, Satagopan JM, Scardino PT, Gerald WL, Reuter VE.

Mod Pathol. 2010 Oct;23(10):1325-33. doi: 10.1038/modpathol.2010.120. Epub 2010 Jun 18.

12.

Identification of DOK genes as lung tumor suppressors.

Berger AH, Niki M, Morotti A, Taylor BS, Socci ND, Viale A, Brennan C, Szoke J, Motoi N, Rothman PB, Teruya-Feldstein J, Gerald WL, Ladanyi M, Pandolfi PP.

Nat Genet. 2010 Mar;42(3):216-23. doi: 10.1038/ng.527. Epub 2010 Feb 7.

13.

Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer.

Reid AH, Attard G, Ambroisine L, Fisher G, Kovacs G, Brewer D, Clark J, Flohr P, Edwards S, Berney DM, Foster CS, Fletcher A, Gerald WL, Møller H, Reuter VE, Scardino PT, Cuzick J, de Bono JS, Cooper CS; Transatlantic Prostate Group.

Br J Cancer. 2010 Feb 16;102(4):678-84. doi: 10.1038/sj.bjc.6605554. Epub 2010 Jan 26.

14.

Enteric neural crest differentiation in ganglioneuromas implicates Hedgehog signaling in peripheral neuroblastic tumor pathogenesis.

Gershon TR, Shiraz A, Qin LX, Gerald WL, Kenney AM, Cheung NK.

PLoS One. 2009 Oct 16;4(10):e7491. doi: 10.1371/journal.pone.0007491. Erratum in: PLoS One. 2014 Jul 25;9(7):e103881. Shirazi, Arash [corrected to Shiraz, Ashton].

15.

NF-kappaB regulates androgen receptor expression and prostate cancer growth.

Zhang L, Altuwaijri S, Deng F, Chen L, Lal P, Bhanot UK, Korets R, Wenske S, Lilja HG, Chang C, Scher HI, Gerald WL.

Am J Pathol. 2009 Aug;175(2):489-99. doi: 10.2353/ajpath.2009.080727. Epub 2009 Jul 23.

16.

WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis.

Nguyen DX, Chiang AC, Zhang XH, Kim JY, Kris MG, Ladanyi M, Gerald WL, Massagué J.

Cell. 2009 Jul 10;138(1):51-62. doi: 10.1016/j.cell.2009.04.030. Epub 2009 Jul 2.

17.

The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers.

Veeriah S, Brennan C, Meng S, Singh B, Fagin JA, Solit DB, Paty PB, Rohle D, Vivanco I, Chmielecki J, Pao W, Ladanyi M, Gerald WL, Liau L, Cloughesy TC, Mischel PS, Sander C, Taylor B, Schultz N, Major J, Heguy A, Fang F, Mellinghoff IK, Chan TA.

Proc Natl Acad Sci U S A. 2009 Jun 9;106(23):9435-40. doi: 10.1073/pnas.0900571106. Epub 2009 May 28.

18.

Genes that mediate breast cancer metastasis to the brain.

Bos PD, Zhang XH, Nadal C, Shu W, Gomis RR, Nguyen DX, Minn AJ, van de Vijver MJ, Gerald WL, Foekens JA, Massagué J.

Nature. 2009 Jun 18;459(7249):1005-9. doi: 10.1038/nature08021. Epub 2009 May 6.

19.

Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis.

King JC, Xu J, Wongvipat J, Hieronymus H, Carver BS, Leung DH, Taylor BS, Sander C, Cardiff RD, Couto SS, Gerald WL, Sawyers CL.

Nat Genet. 2009 May;41(5):524-6. doi: 10.1038/ng.371. Epub 2009 Apr 26.

20.

Association of survival and disease progression with chromosomal instability: a genomic exploration of colorectal cancer.

Sheffer M, Bacolod MD, Zuk O, Giardina SF, Pincas H, Barany F, Paty PB, Gerald WL, Notterman DA, Domany E.

Proc Natl Acad Sci U S A. 2009 Apr 28;106(17):7131-6. doi: 10.1073/pnas.0902232106. Epub 2009 Apr 9.

21.

Genome-wide impact of androgen receptor trapped clone-27 loss on androgen-regulated transcription in prostate cancer cells.

Nwachukwu JC, Mita P, Ruoff R, Ha S, Wang Q, Huang SJ, Taneja SS, Brown M, Gerald WL, Garabedian MJ, Logan SK.

Cancer Res. 2009 Apr 1;69(7):3140-7. doi: 10.1158/0008-5472.CAN-08-3738. Epub 2009 Mar 24.

22.

Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer.

Gonzalez-Angulo AM, Stemke-Hale K, Palla SL, Carey M, Agarwal R, Meric-Berstam F, Traina TA, Hudis C, Hortobagyi GN, Gerald WL, Mills GB, Hennessy BT.

Clin Cancer Res. 2009 Apr 1;15(7):2472-8. doi: 10.1158/1078-0432.CCR-08-1763. Epub 2009 Mar 10.

23.

Specific gene expression profiles and chromosomal abnormalities are associated with infant disseminated neuroblastoma.

Lavarino C, Cheung NK, Garcia I, Domenech G, de Torres C, Alaminos M, Rios J, Gerald WL, Kushner B, LaQuaglia M, Mora J.

BMC Cancer. 2009 Feb 3;9:44. doi: 10.1186/1471-2407-9-44.

24.

TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy.

Gopalan A, Leversha MA, Satagopan JM, Zhou Q, Al-Ahmadie HA, Fine SW, Eastham JA, Scardino PT, Scher HI, Tickoo SK, Reuter VE, Gerald WL.

Cancer Res. 2009 Feb 15;69(4):1400-6. doi: 10.1158/0008-5472.CAN-08-2467. Epub 2009 Feb 3.

25.

Solitary relapse of desmoplastic small round cell tumor detected by positron emission tomography/computed tomography.

Kushner BH, Laquaglia MP, Gerald WL, Kramer K, Modak S, Cheung NK.

J Clin Oncol. 2008 Oct 20;26(30):4995-6. doi: 10.1200/JCO.2008.17.9457. Epub 2008 Sep 22. No abstract available.

26.

Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model.

Kinkade CW, Castillo-Martin M, Puzio-Kuter A, Yan J, Foster TH, Gao H, Sun Y, Ouyang X, Gerald WL, Cordon-Cardo C, Abate-Shen C.

J Clin Invest. 2008 Sep;118(9):3051-64. doi: 10.1172/JCI34764.

27.

Differential expression of genes mapping to recurrently abnormal chromosomal regions characterize neuroblastic tumours with distinct ploidy status.

Lavarino C, Garcia I, Mackintosh C, Cheung NK, Domenech G, Ríos J, Perez N, Rodríguez E, de Torres C, Gerald WL, Tuset E, Acosta S, Beleta H, de Alava E, Mora J.

BMC Med Genomics. 2008 Aug 13;1:36. doi: 10.1186/1755-8794-1-36.

28.

Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study.

Director's Challenge Consortium for the Molecular Classification of Lung Adenocarcinoma, Shedden K, Taylor JM, Enkemann SA, Tsao MS, Yeatman TJ, Gerald WL, Eschrich S, Jurisica I, Giordano TJ, Misek DE, Chang AC, Zhu CQ, Strumpf D, Hanash S, Shepherd FA, Ding K, Seymour L, Naoki K, Pennell N, Weir B, Verhaak R, Ladd-Acosta C, Golub T, Gruidl M, Sharma A, Szoke J, Zakowski M, Rusch V, Kris M, Viale A, Motoi N, Travis W, Conley B, Seshan VE, Meyerson M, Kuick R, Dobbin KK, Lively T, Jacobson JW, Beer DG.

Nat Med. 2008 Aug;14(8):822-7. doi: 10.1038/nm.1790. Epub 2008 Jul 20.

29.

KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis.

Narla G, DiFeo A, Fernandez Y, Dhanasekaran S, Huang F, Sangodkar J, Hod E, Leake D, Friedman SL, Hall SJ, Chinnaiyan AM, Gerald WL, Rubin MA, Martignetti JA.

J Clin Invest. 2008 Aug;118(8):2711-21. doi: 10.1172/JCI34780.

30.

The role of SPINK1 in ETS rearrangement-negative prostate cancers.

Tomlins SA, Rhodes DR, Yu J, Varambally S, Mehra R, Perner S, Demichelis F, Helgeson BE, Laxman B, Morris DS, Cao Q, Cao X, Andrén O, Fall K, Johnson L, Wei JT, Shah RB, Al-Ahmadie H, Eastham JA, Eggener SE, Fine SW, Hotakainen K, Stenman UH, Tsodikov A, Gerald WL, Lilja H, Reuter VE, Kantoff PW, Scardino PT, Rubin MA, Bjartell AS, Chinnaiyan AM.

Cancer Cell. 2008 Jun;13(6):519-28. doi: 10.1016/j.ccr.2008.04.016.

31.

TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4.

Padua D, Zhang XH, Wang Q, Nadal C, Gerald WL, Gomis RR, Massagué J.

Cell. 2008 Apr 4;133(1):66-77. doi: 10.1016/j.cell.2008.01.046.

32.

Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis.

Motoi N, Szoke J, Riely GJ, Seshan VE, Kris MG, Rusch VW, Gerald WL, Travis WD.

Am J Surg Pathol. 2008 Jun;32(6):810-27. doi: 10.1097/PAS.0b013e31815cb162.

PMID:
18391747
33.

Activator protein-1 transcription factors are associated with progression and recurrence of prostate cancer.

Ouyang X, Jessen WJ, Al-Ahmadie H, Serio AM, Lin Y, Shih WJ, Reuter VE, Scardino PT, Shen MM, Aronow BJ, Vickers AJ, Gerald WL, Abate-Shen C.

Cancer Res. 2008 Apr 1;68(7):2132-44. doi: 10.1158/0008-5472.CAN-07-6055.

34.

The signatures of autozygosity among patients with colorectal cancer.

Bacolod MD, Schemmann GS, Wang S, Shattock R, Giardina SF, Zeng Z, Shia J, Stengel RF, Gerry N, Hoh J, Kirchhoff T, Gold B, Christman MF, Offit K, Gerald WL, Notterman DA, Ott J, Paty PB, Barany F.

Cancer Res. 2008 Apr 15;68(8):2610-21. doi: 10.1158/0008-5472.CAN-07-5250. Epub 2008 Mar 28.

35.

Epidermal growth factor receptor activation in prostate cancer by three novel missense mutations.

Cai CQ, Peng Y, Buckley MT, Wei J, Chen F, Liebes L, Gerald WL, Pincus MR, Osman I, Lee P.

Oncogene. 2008 May 15;27(22):3201-10. doi: 10.1038/sj.onc.1210983. Epub 2008 Jan 14.

PMID:
18193092
36.

Endogenous human microRNAs that suppress breast cancer metastasis.

Tavazoie SF, Alarcón C, Oskarsson T, Padua D, Wang Q, Bos PD, Gerald WL, Massagué J.

Nature. 2008 Jan 10;451(7175):147-52. doi: 10.1038/nature06487.

37.

Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas.

Gao SP, Mark KG, Leslie K, Pao W, Motoi N, Gerald WL, Travis WD, Bornmann W, Veach D, Clarkson B, Bromberg JF.

J Clin Invest. 2007 Dec;117(12):3846-56.

38.

Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8.

Kramer K, Humm JL, Souweidane MM, Zanzonico PB, Dunkel IJ, Gerald WL, Khakoo Y, Yeh SD, Yeung HW, Finn RD, Wolden SL, Larson SM, Cheung NK.

J Clin Oncol. 2007 Dec 1;25(34):5465-70.

PMID:
18048828
39.

ID genes mediate tumor reinitiation during breast cancer lung metastasis.

Gupta GP, Perk J, Acharyya S, de Candia P, Mittal V, Todorova-Manova K, Gerald WL, Brogi E, Benezra R, Massagué J.

Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19506-11. Epub 2007 Nov 28.

40.

Control of androgen receptor signaling in prostate cancer by the cochaperone small glutamine rich tetratricopeptide repeat containing protein alpha.

Buchanan G, Ricciardelli C, Harris JM, Prescott J, Yu ZC, Jia L, Butler LM, Marshall VR, Scher HI, Gerald WL, Coetzee GA, Tilley WD.

Cancer Res. 2007 Oct 15;67(20):10087-96.

41.

Oncogenic cooperation and coamplification of developmental transcription factor genes in lung cancer.

Kendall J, Liu Q, Bakleh A, Krasnitz A, Nguyen KC, Lakshmi B, Gerald WL, Powers S, Mu D.

Proc Natl Acad Sci U S A. 2007 Oct 16;104(42):16663-8. Epub 2007 Oct 9.

42.

Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer.

Attard G, Clark J, Ambroisine L, Fisher G, Kovacs G, Flohr P, Berney D, Foster CS, Fletcher A, Gerald WL, Moller H, Reuter V, De Bono JS, Scardino P, Cuzick J, Cooper CS; Transatlantic Prostate Group.

Oncogene. 2008 Jan 10;27(3):253-63. Epub 2007 Jul 16.

43.

Association of cysteine-rich secretory protein 3 and beta-microseminoprotein with outcome after radical prostatectomy.

Bjartell AS, Al-Ahmadie H, Serio AM, Eastham JA, Eggener SE, Fine SW, Udby L, Gerald WL, Vickers AJ, Lilja H, Reuter VE, Scardino PT.

Clin Cancer Res. 2007 Jul 15;13(14):4130-8.

44.

Identification of novel androgen receptor target genes in prostate cancer.

Jariwala U, Prescott J, Jia L, Barski A, Pregizer S, Cogan JP, Arasheben A, Tilley WD, Scher HI, Gerald WL, Buchanan G, Coetzee GA, Frenkel B.

Mol Cancer. 2007 Jun 6;6:39.

45.

Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer.

Berishaj M, Gao SP, Ahmed S, Leslie K, Al-Ahmadie H, Gerald WL, Bornmann W, Bromberg JF.

Breast Cancer Res. 2007;9(3):R32.

46.

Differential expression of alpha-methylacyl-coenzyme A racemase in colorectal carcinoma bears clinical and pathologic significance.

Lin A, Weiser MR, Klimstra DS, Paty PB, Tang LH, Al-Ahmadie H, Hoo Park S, Guillem JG, Temple L, Wong WD, Gerald WL, Shia J.

Hum Pathol. 2007 Jun;38(6):850-6. Epub 2007 Apr 18.

PMID:
17442371
47.
48.

The 2006 Fred Waldorf Stewart Award recipient Juan Rosai, MD.

Klimstra DS, Gerald WL.

Am J Surg Pathol. 2007 Apr;31(4):649-51. No abstract available.

PMID:
17414120
49.

Comprehensive analysis of tumoral DNA content reveals clonal ploidy heterogeneity as a marker with prognostic significance in locoregional neuroblastoma.

Mora J, Lavarino C, Alaminos M, Cheung NK, Ríos J, de Torres C, Illei P, Juan G, Gerald WL.

Genes Chromosomes Cancer. 2007 Apr;46(4):385-96.

PMID:
17243159
50.

An X chromosome gene, WTX, is commonly inactivated in Wilms tumor.

Rivera MN, Kim WJ, Wells J, Driscoll DR, Brannigan BW, Han M, Kim JC, Feinberg AP, Gerald WL, Vargas SO, Chin L, Iafrate AJ, Bell DW, Haber DA.

Science. 2007 Feb 2;315(5812):642-5. Epub 2007 Jan 4.

Supplemental Content

Loading ...
Support Center